What the FDA labels say about taking them together
Glucagon and insulin human
Insulin human's FDA label of March 7, 2025 names glucagon in its drug interactions section; the glucagon labels PlainMeds reads (4) do not name insulin human. The insulin human label: “Drugs That May Decrease the Blood Glucose Lowering Effect of HUMULIN R U 500 Drugs: Atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives …”
Check it at the source: the glucagon FDA label on DailyMed (effective August 11, 2026, Amphastar Pharmaceuticals, Inc.); the insulin human FDA label on DailyMed (effective March 7, 2025, Baxter Healthcare Corporation).
What does the glucagon label say about insulin human?
Glucagon's label (effective August 11, 2026) and its 3 other brand-application labels do not name insulin human in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Glucagon), Amphastar Pharmaceuticals, Inc., effective August 11, 2026 (SPL set 8cc40354-b5ac-45b6-a211-93b44444f2a3), via openFDA; the full label on DailyMed
What does the insulin human label say about glucagon?
Insulin human label, drug interactionsDrugs that May Decrease the Blood Glucose Lowering Effect of MYXREDLIN Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when MYXREDLIN is co-administered with these drugs.
Source: FDA drug label (Afrezza, BLA022472), Mannkind Corporation, effective May 30, 2026 (SPL set 29f4637b-e204-425b-b89c-7238008d8c10), via openFDA
Source: FDA drug label (Humulin R U-500 Kwikpen, BLA018780), Eli Lilly and Company, effective July 1, 2026 (SPL set b60e8dd0-1d48-4dc9-87fd-e14675255e8c), via openFDA
Source: FDA drug label (MYXREDLIN), Baxter Healthcare Corporation, effective March 7, 2025 (SPL set afca6e80-a802-49fb-a978-5fe28a173001), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Glucagon | Insulin human | |
|---|---|---|
| Labeled for | n/a | Type 2 diabetes, Type 1 diabetes |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $154.20 per kit 1 mg emergency kit | $4.26 per mL 70-30 vial |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once